相关实验视频

Updated: Sep 9, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

在免疫性血小板缺陷患者中,剂量优化的复合人体血小板蛋白对eltrombopag:多中心随机对照试验 (TE- ITP研究)

Yunfei Chen¹, Ting Sun¹, Da Gao²

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

EClinicalMedicine

|September 2, 2025

概括

与eltrombopag相比,个性化复合人体血小板蛋白 (rhTPO) 疗法显著加快了血小板数的恢复,降低了免疫血小板缺血 (ITP) 患者的出血风险.

科学领域:

血液学
临床药理学
内部医学

背景情况:

免疫性血小板缺血 (ITP) 是一种出血疾病.
复合人体血栓形成素 (rhTPO) 在治疗ITP方面已显示出有效性.
优化 rhTPO 剂量对于患者的结果至关重要.

研究的目的:

在成年 ITP 患者中评估灵活,个性化的 rhTPO 治疗方案.
为了比较个性化rhTPO与eltrombopag的疗效和安全性.
确定达到目标血小板数量的时间.

主要方法:

一项随机对照试验 (TE- ITP) 涉及157名成年ITP患者.
根据血小板数量进行剂量调整,患者接受了个性化的rhTPO或eltrombopag.
主要终点是血小板计数达到≥50 × 10 9/ L的时间.

主要成果:

个性化的rhTPO比eltrombopag (15天) 更快地达到主要终点 (7天) (p < 0. 001).
在 rhTPO 组中,出血风险显著降低 (OR 0. 523, p < 0. 001).
在45. 7%的rhTPO患者和60. 8%的eltrombopag患者中报告了不良反应.

结论:

针对个体的rhTPO剂量策略优于eltrombopag,可快速增加血小板ITP.
这种个性化的rhTPO疗法提供了更好的安全性,降低了出血风险.
优化的rhTPO为成年人提供了更有效的治疗选择.

关键词:

艾尔特罗姆波巴格免疫性血小板减少个性化剂量血小板数量复合人体血栓形成素

更多相关视频

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...